Related Experiment Video

Updated: May 24, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Non-small cell lung carcinoma therapy using mTOR-siRNA

Hirochika Matsubara1, Kenji Sakakibara, Tamo Kunimitsu

  • 1Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. hmatsu@yamanashi.ac.jp

International Journal of Clinical and Experimental Pathology
|March 9, 2012
PubMed

Insights

Small interfering RNA (siRNA) targeting the mammalian target of rapamycin (mTOR) effectively inhibits non-small-cell lung cancer (NSCLC) cell proliferation and migration while increasing apoptosis in vitro.

Area of Science:

  • Oncology
  • Molecular Biology
  • RNA Therapeutics

Background:

  • Molecular targeting agents are crucial in non-small-cell lung cancer (NSCLC) therapy.
  • Inhibition of the mammalian target of rapamycin (mTOR) is a key strategy in NSCLC treatment.
  • Small interfering RNA (siRNA) offers a targeted approach to inhibit specific molecular pathways with potentially fewer side effects.

Purpose of the Study:

  • To evaluate the antitumor effects of a small interfering RNA (siRNA) specifically designed to inhibit mTOR in NSCLC cells.
  • To assess the impact of mTOR-siRNA on NSCLC cell proliferation, apoptosis, and migration in vitro.
  • To determine the potential of mTOR-siRNA as an alternative therapeutic strategy for NSCLC.

Main Methods:

  • Transfection of NSCLC cells with mTOR-siRNA.
  • Quantification of cell proliferation by counting cells after 6 days of culture.
  • Assessment of apoptosis using DNA-histone complex detection via absorption spectrometry.
  • Evaluation of cell migration using a commercial chemotaxis assay kit.

Main Results:

  • mTOR-siRNA transfection resulted in a significant decrease in NSCLC cell proliferation (37.3%, p=0.034).
  • Apoptosis levels in NSCLC cells increased by 16.7% (p=0.016) following mTOR-siRNA transfection.
  • Cell migration was significantly inhibited by 39.2% (p=0.0001) after mTOR-siRNA treatment.

Conclusions:

  • mTOR-siRNA effectively induces apoptosis and inhibits proliferation and migration of NSCLC cells in vitro.
  • These findings support the potential of mTOR-siRNA as a novel therapeutic agent for NSCLC.
  • Further research into mTOR-siRNA could lead to optimized cancer therapies maximizing mTOR inhibition's antineoplastic effects.
Keywords:
mTORnon-small-cell lung cancersiRNA

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...